Who we are…
Xiconic Pharmaceuticals was founded in 2016 to advance a key discovery by Dr. Joseph Bertino and was formed as a Delaware corporation in 2019.
Dr. Bertino and colleagues discovered a novel tumor antigen known as activated matriptase (actM) that is overexpressed almost exclusively on tumor cells and could lead to the development of treatments for various cancer indications.
Xiconic’s lead compound, XCN-010, is a Matriptimab™-MMAE antibody-drug conjugate targeting human actM.
Xiconic has licensed key XCN-010 intellectual property from Rutgers and Georgetown universities.
Compelling preclinical data in cancer models supports clinical development for multiple indications.